The degree of diagnostic radiation exposure in children with infl ammatory bowel diseases (IBD) is largely unknown. In this study, we describe this exposure in a population-based sample of children with IBD and determine the characteristics associated with moderate radiation exposure.
INTRODUCTION
Infl ammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn ' s disease (CD), are chronic autoimmune diseases of the intestines that can begin in childhood. Both follow a fl uctuating, life-long course with multiple acute episodes or " fl ares " interspersed between periods of quiescence. Advances in the treatment of IBD have led to novel therapeutics that may alter the course of the disease. However, individuals with IBD have an increased risk of developing various malignancies, both from the disease itself and from therapeutics used to treat the disease (1 -5) .
Diagnostic imaging, including the use of radiological tests such as fl uoroscopy and computed tomography (CT), has become an increasingly important component of the evaluaDiagnostic Ionizing Radiation Exposure in a Population-Based Sample of Children With Infl ammatory Bowel Diseases tion and management of IBD. However, diagnostic ionizing radiation represents an additional IBD-related exposure with carcinogenic potential (6, 7) . Of particular concern is CT, which can impart radiation doses that are over 100 times that of a conventional X-ray fi lm (8) . Ionizing radiation increases the risk of several types of malignancies, including hematologic and solid-organ cancers. Observational studies of atomic bomb and nuclear disaster survivors, as well as radiation industry workers have shown an increased risk of death from malignancy with even moderate exposures (9 -12) . Low-level, protracted radiation exposures (such as those associated with medical imaging) have also been associated with malignancy (9,13 -16) .
Th e pediatric population is particularly vulnerable to the eff ects of ionizing radiation (11, 17) . Compared with adults, children have more biologically active tissue with less intervening space between susceptible organs. In addition, they have a lifetime in which to develop radiation-induced complications. Consequently, it has been estimated that the ionizing radiation imparted in one CT before the age of 15 incurs a 1 in 1,500 excess risk of cancer mortality (18) .
Despite these risks of radiation, the use of CT has increased in the general US population by approximately 20-fold over the last 25 years (8) . Even more concerning is that between 6 and 11 % of CT scans in the United States are performed in children (19) , the subgroup of the population with the highest risk. Several recent studies have shown that the use of CT in adult IBD patients has far outpaced CT use in the general population. One tertiary IBD referral center showed a 380 % increase in the use of CT over a 15-year period (7) , and another population-based investigation reported an 870 % increase in the use of CT enterography (20) . However, the use of diagnostic ionizing radiation in US children with IBD remains poorly characterized.
Given the exponential increase in diagnostic radiation exposure by adult IBD patients, and the particular concern for malignancy risk in pediatric patients, we sought to describe the use of diagnostic ionizing radiation in a population-based sample of children with UC and CD. We also examined the patient characteristics associated with moderate-dose imaging exposure.
METHODS

Study design and data source
In this cross-sectional study, we analyzed the medical, surgical, and pharmaceutical insurance claims contained in the PharMetrics Patient-Centric Database (IMS Health, Watertown, MA) for the period 1 January 2003 through 31 December 2004. Earlier studies have used this longitudinal, patient-level database to examine the prevalence and costs of IBD (21) . At the time of this study, the PharMetrics database included claims from 87 health plans in 33 states and was reported to be representative of the national commercially insured population on a variety of demographic measures, including geographic region, age, gender, and health plan type (22) .
Patient selection
All children aged 18 years and under at the time of identifi cation with continuous health plan enrollment between 1 January 2003 and 1 December 2004 were eligible for inclusion in this analysis. We identifi ed cases of UC and CD using a previously described administrative claims ascertainment algorithm (21) . Th is defi nition included patients with at least three health care contacts, on diff erent days, associated with an International Classifi cation of Diseases, 9th Revision, (ICD-9) Clinical Modifi cation diagnosis code for UC (556.xx) or CD (555.xx), or patients with at least one claim for UC or CD and at least one pharmacy claim for any of the following medications: mesalamine, osalazine, balsalazide, sulfasalazine, 6-mercaptopurine, azathioprine, infl iximab, adalimumab, and enteral budesonide. For patients who had claims for both UC and CD, disease assignment was made according to the majority of the last nine claims.
Exposure ascertainment
To determine outcomes and exposures of interest, we classifi ed each claim as inpatient, outpatient, or pharmaceutical according to CPT (Current Procedural Terminology), HCPCS (Healthcare Common Procedure Coding System), or NDC (National Drug Codes). We identifi ed several exposures of interest within our study population, including age, gender, geographical region (northeast, south, midwest, and west), the requirement for hospitalization with a primary diagnosis of UC (556.xx) or CD (555.xx), emergency department (ED) encounters that did not result in hospitalization, and the requirement for inpatient gastrointestinal (GI) surgery (one or more claims during a period of any-cause hospitalization that contained a procedure code for a GI operation, excluding surgery of the liver, biliary tract, and pancreas).
We also examined patient exposure to IBD-specifi c medical therapy, including oral or rectal salicylates (mesalamine, osalazine, balsalazide, or sulfasalazine), immunomodulators (6-mercaptopurine, azathioprine, or methotrexate), anti-TNF agents (infl iximab or adalimumab), oral steroids, and enteralrelease budesonide. Subjects were considered exposed to medical therapy if they had at least two pharmacy claims for the medications over the time of the study.
Outcome description
All occurrences of 23 diff erent types of diagnostic imaging studies were identifi ed through CPT codes, including CT of the abdomen and / or pelvis; CT angiogram of the abdomen, mesentery, or aorta; CT enterography; abdominal X-ray, fi stulogram, or sinogram; upper GI series; upper GI series with small-bowel follow-through; small-bowel follow-through without upper GI series; contrast enema; endoscopic retrograde cholangiopancreatography, cholangiography, or cholecystography; small-bowel enteroclysis, as well as selected non-GI studies. A complete list of CPT classifi cation codes is included in the supplemental material (See Supplementary are oft en submitted for a single encounter (facility fees, technical services, professional services, etc), we counted all claims for the same type of imaging test occurring on the same day as a single study. When both a CT of the abdomen and a CT of the pelvis occurred on the same day, they were counted as a single abdominopelvic CT.
Moderate-dose radiation imaging was defi ned as at least one CT or three fl uoroscopic procedures during the 2-year observation period. We based this defi nition on the data from the atomic bomb survivor cohort, indicating that the ionizing radiation dose imparted by one abdominal CT before the age of 15 carries a 1 in 1,500 risk of death from malignancy, with risk falling logarithmically into one ' s third decade of life (18) . Also, published estimates of fl uoroscopic and CT eff ective doses indicate that, on average, fl uoroscopic procedures impart lower doses of ionizing radiation than CT scans (23 -28) . CT scans impart 100 -150 times the dose of one conventional X-ray or bone mineral density exam; therefore, X-rays and bone mineral density exams were not included in the defi nition of moderatedose radiation imaging (20, 29) .
Statistical analysis
Standard univariate statistics were performed, including calculations of means, medians, proportions, ranges, and interquartile ranges. Th e one continuous variable, age, was examined in its simple continuous form as well as categorical forms to determine the most valid and precise coding structure. Bivariate statistics (Pearson ' s 2 , Wilcoxon rank-sum, or t -tests based on variable type) were used to assess for statistical associations between the receipt of moderate radiation imaging and the exposures of interest.
Multivariable logistic regression models estimating prevalence odds ratios (ORs) were performed separately within the UC and CD samples. Methotrexate, azathioprine, and 6-mercaptopurine were analyzed as " immunomodulators, " and adalimumab and infl iximab were analyzed as " anti-TNF agents. " Adalimumab, infl iximab, and budesonide were used rarely to treat UC at the time of the study and were excluded from the UC model. Each exposure was considered of potential interest; therefore, all potential risk factors were retained in the fi nal model. Stata statistical soft ware (Stata Ver. 10.0, College Station, TX) was used for all statistical analyses. Th e study protocol was granted exemption from review by the Institutional Review Board at the University of North Carolina at Chapel Hill on 9 September 2008, because it involved the use of existing deidentifi ed data.
RESULTS
Sample characteristics
We identifi ed 1,593 children with IBD (628 UC and 965 CD). Th e mean age was 14 years, with a standard deviation of 3 years ( Table 1 ). In total, 45 % of the sample was female, and patients were relatively evenly divided among the four regional areas (34.2 % northeast, 16.8 % west, 21.4 % south, and 27.6 % midwest). Th e only statistical diff erences between the UC and CD groups were in the use of IBD-specifi c medications. More children with CD were exposed to immunomodulators (43 vs. 26 % , P < 0.05), anti-TNF agents (15.4 vs. 3.2 % , P < 0.05), and budesonide (9 vs. 4 % , P < 0.05). Conversely, more children with UC were exposed to rectal salicylates (26 vs. 6 % , P < 0.05). Approximately, one-quarter of the sample was hospitalized at least once over the 2-year period, 37 % had at least one ED encounter that did not result in hospitalization, and 8 % underwent an inpatient GI surgery.
Diagnostic radiation exposure
Over the 2-year period, 23 % of children with UC and 34 % of children with CD were exposed to moderate radiation imaging (OR 1.71, 95 % confi dence interval (CI), 1.36 -2.1). In total, 49 % of UC subjects and 33 % of CD subjects received no imaging studies. Th ere was a median of 1 CT, 1 fl uoroscopy, and 2 X-rays in the group who were exposed to any imaging. When we examined the distribution by study type, X-ray exams (plain fi lm exams of chest, abdomen or pelvis, and bone mineral density exams) were the most commonly ordered study (60 % of imaging in UC; 48 % in CD) ( Figure 1 ). CT comprised 25 % of all studies ordered for children with UC and 28 % of all studies ordered for children with CD. Fluoroscopic procedures were the least commonly performed study (16 % of imaging in UC; 23 % in CD). In total, 6 % of CD subjects and 5 % of UC subjects underwent three or more CT scans, and 1.8 % of CD subjects and 2.2 % of UC subjects underwent fi ve or more CT scans. Detailed use of all imaging studies over the 2-year period is shown in Tables 2 and 3 .
Factors associated with moderate radiation imaging
The results of multivariable regression modeling for children with CD show that IBD-related hospitalization (OR 4.89, 95 % CI 3.37 -7.09), inpatient GI surgery (OR 2.93, 95 % CI 1.59 -5.39), use of oral steroids (OR 2.25, 95 % CI 1.50 -3.38), ED encounter (OR 2.65, 95 % CI 1.93 -3.64), and the use of enteral budesonide (OR 1.80, 95 % CI 1.10 -3.06) were positively associated with the receipt of moderate-dose radiation imaging, and immunomodulators were negatively associated (OR 0.67, 95 % CI 0.47 -0.97) ( Table 4 ). When we stratifi ed our results by oral steroid use (a marker of disease fl are), we found that the inverse association with immunomodulator use was only present in those patients who did not require steroids during the observation period (unexposed to steroids: OR 0.55, 95 % CI 0.36 -0.85; exposed to steroids 1.36, 95 % CI 0.62 -2.99). Similar point estimates were seen in subjects with UC, though the only statistically significant associations were IBD-related hospitalization (OR 3.04, 95 % CI 1.84 -5.03), surgery (OR 4.13, 95 % CI 1.85 -9.22), and ED encounter (OR 3.27, 95 % CI 2.13 -5.01) ( Table 4 ) .
Age, gender, use of anti-TNF agents, and use of oral or rectal salicylates were not associated with diagnostic radiation exposure in UC or CD. Regional variation was modest ( Table 4 ) .
We repeated the analyses using a defi nition of moderatedose radiation exposure as at least one CT or two fl uoroscopic studies over the 2-year period. Th is resulted in an additional 29 children with CD (2 % ) and 11 children with UC (2 % ) classifi ed as receiving moderate-dose radiation exposure. Th e addition of these patients did not change the eff ect estimates in our multivariable models.
Imaging performed in patients without obvious risk factors may represent " overuse " (30) of radiological testing, and thus unnecessary radiation exposure. Th erefore, we sought to further characterize the use of radiological studies in patients without hospitalization, surgery, ED encounters, and oral steroid use. In this low-risk group, 13 % of children with CD and 7 % of children with UC received moderate radiation exposure through diagnostic imaging.
DISCUSSION
Th is population-based analysis has shown that approximately one-third of commercially insured US children with CD and one-quarter with UC were exposed to at least moderate amounts of diagnostic ionizing radiation over a 2-year time period. Indicators of severe disease are associated with increased imaging, including hospitalization, surgery, ED encounters, and use of steroids. Th e use of immunomodulators is negatively associated with radiation exposure in children with CD, which may refl ect the growing body of literature showing that immunomodulators are eff ective in maintaining disease remission (31, 32) .
Th e widespread use of CT and other imaging modalities in pediatric IBD patients is consistent with the emerging literature in this area. Newnham et al. (6) were the fi rst to highlight the use of diagnostic radiation exposure in IBD patients. Th ey reported the imaging history of 62 subjects with CD and 48 subjects with UC (mean age 39 years, range 16 -84 years) at a single, tertiary-care IBD referral center in Australia. Using a defi nition of " high risk " exposure as a cumulative dose > 50 mSv, they estimated that 11 % of their sample was exposed to high levels of diagnostic ionizing radiation. Factors associated with high-level exposure included a diagnosis of CD vs. UC (OR for UC 0.33, 95 % CI 0.05 -2.01) and undergoing surgery (OR 3.01, 95 % CI 0.67 -13.5). Th ese results were not signifi cant overall, likely due the small sample size of the study.
Two additional studies have confi rmed these fi ndings and have shown the increase in CT use over time. One tertiary referral center in Ireland reported an increase in the use of CT by 380 % from the period spanning 1992 -1997 to the period spanning 2002 -2007. Peloquin et al. (20) performed a population-based analysis of diagnostic radiation exposure in IBD patients in Olmstead County, Minnesota, and also showed a large increase in CT utilization.
Our study extends this earlier work in a number of meaningful ways. First, we focus solely on pediatric patients. Th is population, which has been largely neglected in earlier studies, is actually the most vulnerable to the harmful eff ects Over the 2-year period, 1,275 studies were performed in children with UC and 2,137 were performed in children with CD. X-rays were the most commonly ordered study, comprising 60 and 48 % of the studies performed in children with UC and CD, respectively. CT scans comprised 25 % of the total imaging in children with UC and 28 % in children with CD. Fluoroscopic exams were the least commonly ordered study (16 % of studies in children with UC and 23 % of studies in children with CD). CD, Crohn's disease; CT, computed tomography; UC, ulcerative colitis.
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adult reports. Th e higher use of CT (and exposure to radiation) observed in pediatric patients as compared with that in adult patients may be related to the increased severity and extent of disease in children compared with adults, as suggested in a number of recent reports (33, 34) . Alternatively, increased imaging may be a function of time-from-diagnosis. Earlier work from Longobardi et al. (35, 36) has shown that health care resource utilization is most intense in the 2 years aft er diagnosis. Children are more likely than adults to be closer to their time of diagnosis and potentially more likely to undergo imaging. Also, providers may view diagnostic medical imaging as non-invasive and therefore choose radiation-based tests of radiation exposure. We found that CT comprised a significant proportion of imaging tests performed in pediatric IBD patients, particularly in children with CD. Th is partly explains the high proportion of children exposed to moderate ionizing radiation over the 24-month observation period. In addition, CT was used more oft en in this pediatric cohort than has been seen in studies of adults (up to 28 % in our pediatric population vs. 12 -16 % in adults (6,7) ). A cohort eff ect based on the years of study is unlikely to explain this fi nding, as the 2 years of our analysis fell between the study periods of the 
Ionizing Radiation in Children With IBD before other strategies involving more immediate risks from sedation, biopsies, etc. Despite the growing public health concern over the expanding use of high-dose diagnostic radiation, awareness of the risks is low among medical providers and patients. In a 2004 study of abdominal CT imaging in a US ED, 97 % of patients, 91 % of emergency medicine physicians, and 53 % of radiologists did not believe that CT studies could increase the risk of malignancy (37) . Only 7 % of patients remembered discussing radiation risks before the exam. Practitioners in Great Britain showed a similarly poor knowledge of radiation risks (38) . Th is suggests that although concerns for malignancy are of paramount importance with regards to therapeutic decisionmaking, they do not seem to be a high priority with regards to diagnostic decision-making.
Th e data presented in this study indicate that a substantial proportion of children with IBD are exposed to potentially harmful amounts of ionizing radiation as a result of diagnostic testing. Th erefore, as with therapeutic decisions, we advocate that the risks, benefi ts, and alternatives to fl uoroscopic and CT studies be carefully considered. Emerging diagnostic alternatives to these studies include ultrasound and newer MRI imaging modalities where available (39, 40) . Furthermore, a " watch and wait " approach with serial abdominal exams may also be helpful in identifying the possibility of disease complications and informing the need for subsequent imaging studies when this is clinically appropriate. Finally, for instances in which CT and / or fl uoroscopic studies are indicated, radiological protocols that minimize radiation exposure to the lowest extent possible should be used (17) . Indeed, Berdon and Slovis (41) summarized a series on radiation doses from pediatric CT by indicating that as much as 30 % of the dose from pediatric CT could be unnecessary. Th e radiation dose from CT is being addressed on a national level through a number of approaches including the Image Gently campaign (42) .
Th is analysis has a few potential limitations that should be noted. Misclassifi cation of subjects is always of concern when administrative claims are used as the primary data source. Both under-ascertainment of true cases of IBD and misclassifi cation of other diseases as IBD can bias the results of administrative analyses. By requiring multiple diagnosis codes for either CD or UC and including the use of IBD-specifi c medications in our case defi nition algorithm, we attempted to optimize the sensitivity and overall accuracy of our administrative defi nition. Bernstein et al. (43) have used a similar administrative defi nition, which was developed and validated against primary medical record data. Misclassifi cation and / or under-ascertainment of outcomes may also be questioned when administrative databases are used as the primary data source. We feel that this type of bias would have a minimal eff ect on our results as earlier works have shown that administrative claims are reliable when studying procedures that are highly linked to reimbursement, such as diagnostic testing, and are comparable with data found in medical records (44 -46) . together to reduce the radiation dose in pediatric exams, reduce the amount of unnecessary diagnostic testing, and increase the use alternative imaging modalities and / or watchful waiting when appropriate in the management of childhood IBD.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
3 Adults with infl ammatory bowel diseases (IBD) are increasingly exposed to diagnostic medical radiation.
3 Less is known about medical radiation exposure in the community, especially in children.
3 Ionizing radiation, including diagnostic medical radiation, may increase malignancy risk.
3 Children are more vulnerable to the effects of ionizing radiation than adults.
WHAT IS NEW HERE
3 In only 2 years, almost one-third of children with IBD were exposed to moderate diagnostic medical radiation.
3 Computed tomography was used more often than has been seen in studies of adults with IBD.
An additional limitation of this study is that the timing of the exposure in relation to the outcome cannot be determined in a cross-sectional analysis. We believe this to be of little consequence in our study because the burden of ionizing radiation exposure remains substantial regardless of whether the imaging was performed before, during, or aft er the IBD diagnosis. In addition, administrative data contain a paucity of clinical information, such as disease phenotype, extent, severity, and time from diagnosis. Th ese characteristics may be important in identifying children who are more likely to be exposed to multiple diagnostic tests over the course of their disease. A fi nal limitation to our study is that we did not have suffi cient detail to determine whether each diagnostic procedure was medically necessary or informative. However, we did fi nd that 13 % of CD patients and 7 % of UC patients with apparently mild disease (no oral steroid use, ED encounter, hospitalization, or surgery) were exposed to moderate diagnostic radiation over the time period of this study. It is possible that some of the imaging performed on these patients without obvious risk factors may have been avoidable. Indeed, the overuse of diagnostic testing including CT has been reported in the pediatric ED setting (47) . However, a negative imaging study can also prevent unnecessary therapeutic interventions or inpatient admissions.
Our study has several strengths that add to the earlier work in this area. Th is is the largest population-based study of diagnostic radiation use in pediatric IBD subjects. Th e geographical diversity of the study population and the inclusion of patients insured by a number of diff erent health plans of varying structure and size make these results broadly generalizable to the commercially insured population of the United States. In addition, the large sample size in this study allowed us to examine the use and drivers of diagnostic testing in pediatric UC and CD patients separately, an important step in delineating the reasons behind the increased radiation exposure in CD patients. An additional strength of our study is that by using administrative claims, we were able to analyze all radiological examinations performed on each patient regardless of the facility. Th us our study complements single-center studies that only have access to the examinations performed at one facility and cannot capture total exposure when imaging is performed outside of that center.
Over 2 years, a substantial proportion of children with IBD were exposed to ionizing radiation as a result of diagnostic testing. A lifetime of diagnostic testing will magnify the risk. Children with IBD may be seen in numerous care settings, and it is imperative that providers at all levels of care are aware of the potential carcinogenic eff ects of medical radiation. Providers must communicate with each other to coordinate a plan for the diagnosis and management of IBD in children that considers both the risks of diagnostic and therapeutic decisions, as well as the life-long nature of the disease. Although the individual risk of diagnostic radiation exposure to any one child is small, and the risk -benefi t ratio generally favors diagnostic testing, the increasingly large number of exposed children may create a public health concern in the future. It is imperative that providers work
